PARIS--4 Nov--PRNewswire-AsiaNet/InfoQuest
- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA Study
Live Webcast Media Briefing - non-US media only
Wednesday 12 November 2008 - 14.00-15.00am CET
Background:
- AF is a growing health concern directly responsible for increased morbidity and mortality
- There is a need for a global prospective database like RecordAF, which takes a closer look at disease characteristics and how management of AF affects cardiovascular (CV) outcomes
- AF is associated with a high hospitalization burden - 70 percent of AF management costs are driven by hospitalization costs (Ringborg et al. Europace 2008; 10:403-11)
- A further sub-analysis of the ATHENA trial was conducted:
- to better understand the impact of dronedarone on hospitalization of
AF patients particularly on the number and duration of CV and non CV hospitalization nights
- An additional sub-analysis was also conducted to further explore dronedarone's rhythm and rate controlling properties
- The ATHENA study is the first AF trial designed to evaluate the effect of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed that dronedarone (brand name Multaq(R)), a new AAD undergoing the registration process, can significantly improve CV outcomes including reducing the risk of hospitalization and death.
Register on-line in advance of the online event:
1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/onst
age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c72
009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23
2. Click "Register"
3. On the registration form, enter your information then click "Submit"
Once the host approves your registration, you will receive a confirmation email containing instructions on how to join the event (event number and password) on the day of the announcement.
Once logged on, you will also be required to connect to a teleconference in order to participate in the live Q&A session with panellists at the end of the event.
Teleconference dial in number (toll-free):
1) To obtain your teleconference number, register first by following the instructions above.
2) Once connected, a pop-up window will appear
3) Select country of affiliation to obtain local dial-in number
4) Dial-in and enter your login details using the provided number within the pop-up window
Please ensure you log on to the event 15 minutes before the start time so as not to miss valuable information.
IMPORTANT NOTICE:
This event is not part of the official Scientific Sessions 2008 as planned by the AHA Committee on Scientific Sessions Programming
SOURCE: Sanofi-aventis
--Distributed by AsiaNet ( www.asianetnews.net )--